Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

Autor: Antonio Ojea, Santiago Isorna, Jesus Rodriguez-Molina, M. Unda, Jesus Fernandez-Gomez, Rafael Hernandez, Mariano Rabadan, Martínez-Piñeiro Ja, Eduardo Solsona, Rosario Madero, Jose Emilio Camacho, Manuel Montesinos, Miguel Blas, P. Muntanola, Ander Astobieta, C. Pertusa, M. Gonzalez, Anabel Gimeno, Luis Martínez-Piñeiro

Publikováno v: European Urology. 53:992-1002

Objectives To evaluate the prognostic factors of recurrence and progression after intravesical adjuvant bacillus Calmette-Guerin (BCG) immunotherapy in patients with non–muscle-invasive bladder tumors. Methods From February 1990 to May 1999, the Sp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::323a690de0fa63cca4acc606da1bc167
https://doi.org/10.1016/j.eururo.2007.10.006

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

Autor: Jesus Fernandez-Gomez, Jesus Rodriguez-Molina, C. Pertusa, Miguel Blas, M. Unda, Eduardo Solsona, M. Gonzalez, Anabel Gimeno, Luis Martínez-Piñeiro, Antonio Ojea, Mariano Rabadan, Santiago Isorna, Jose Emilio Camacho, Ander Astobieta, J.A. Portillo, P. Muntanola, Martínez-Piñeiro Ja, Rosario Madero, Manuel Montesinos

Publikováno v: International braz j urol, Volume: 37, Issue: 5, Pages: 671-672, Published: OCT 2011
International Brazilian Journal of Urology, Vol 37, Iss 5, Pp 671-672 (2011)
International braz j urol v.37 n.5 2011
International Braz J Urol
Sociedade Brasileira de Urologia (SBU)
instacron:SBU

Background European Organization for Research and Treatment of Cancer (EORTC) risk tables only included 171 patients treated with bacillus Calmette-Guerin (BCG) for non–muscle-invasive bladder cancer (NMIBC). Objective To evaluate the external vali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106edbb0be3a0ba9640126d71576c546
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000500025&lng=en&tlng=en

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

Autor: C. Pertusa, Santiago Isorna, Mariano Rabadan, Rosario Madero, Marcelino Gonzalez Martin, For Club Urológico Español de Tratamiento Oncológico (Cueto), Ander Astobieta, Jesús María Fernández Gómez, Rafael Hernandez Rodríguez, Salvador Arribas, Jesús Rodríguez Molina, Luis Martínez-Piñeiro, Martínez-Piñeiro Ja, Eduardo Solsona, Anabel Gimeno Collado, Nicolas Flores, Jose Emilio Camacho

Publikováno v: The Journal of urology. 174(4 Pt 1)

We determined if a third of the dose of intravesical bacillus Calmette-Guerin (BCG) has the same efficacy than a standard dose for decreasing the risk of recurrence and progression after transurethral resection in patients with superficial high risk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4091ad04a8f16e121d23d296702e8029
https://pubmed.ncbi.nlm.nih.gov/16600806

PREDICTION OF RECURRENCE AND PROGRESSION OF NON- MUSCLE INVASIVE BLADDER CANCER IN PATIENTS TREATED WITH BACILLUS CALMETTE-GUÉRIN: A SCORING SYSTEM BASED ON MULTIVARIATE ANALYSIS OF DATA FROM FOUR RANDOMISED CUETO TRIALS

Autor: Rosario Madero, Antonio Ojea, J.M. Fernandez-Gomez, A. Gimeno, Jesus Rodriguez-Molina, Manuel Montesinos, C. Pertusa, Santiago Isorna, Miguel Blas, Luis Martínez-Piñeiro, M. Gonzalez, Martínez-Piñeiro Ja, Ander Astobieta, Jose Emilio Camacho, P. Muntanola, R. Hernandez, Mariano Rabadan, Eduardo Solsona

Publikováno v: European Urology Supplements. 7:298

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7685f4ee63696bb11fd40c0c7cc53304
https://doi.org/10.1016/s1569-9056(08)60906-9

Comparison of a standard BCG dose (81 MG) versus a three-fold reduced dose (27 MG) in high risk superficial bladder cancer (TIG3, TIS), A cueto prospective randomised study #95012

Autor: Santiago Isorna, J.J. Camacho, J. Rodriguez Molina, Ander Astobieta, Luis Martínez-Piñeiro, J.M. Fernández Gómez, M. González Martin, Nicolas Flores, C. Pertusa, Eduardo Solsona, Martínez-Piñeiro Ja, Mariano Rabadan, R. Hernández Rodríguez, A. Gimeno

Publikováno v: European Urology Supplements. 2:190

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0534b79602b9267e1a7432d75c4e79d0
https://doi.org/10.1016/s1569-9056(03)80754-6